Inogen Q2 2026 Earnings: International Growth Supports a Higher EBITDA Outlook

Inogen (NASDAQ: INGN) reported Q2 2026 revenue of $95.1 million, up 3.0% year over year, while its diluted GAAP loss per share narrowed to $0.14 from $0.15 for the quarter ended June 30. International sales and a higher gross margin supported the improvement, although U.S. sales and rental revenue remained below the prior-year period.

Core earnings data

Revenue growth was driven primarily by higher international demand for portable oxygen concentrators and favorable foreign-exchange rates. Total revenue increased only 0.6% on a constant-currency basis, compared with the reported increase of 3.0%.

Profitability improved at the gross-margin and operating levels. Adjusted EBITDA rose 15.2%, but quarterly operating cash flow declined from the prior-year period even as free cash flow increased from a relatively low base.

All figures in the table are quarterly. Adjusted EBITDA and free cash flow are non-GAAP measures.

Business and geographic performance

International sales were the clear growth driver, increasing 14.8% as reported and 8.3% at constant currency. That expansion more than offset lower U.S. sales and an 11.8% decline in U.S. rental revenue.

Portable unit volume grew faster than total revenue, but the shrinking rental patient base continued to pressure the recurring U.S. rental business. Inogen said it was gaining traction with U.S. distributors and its expanded portfolio, though it did not quantify the revenue contribution from individual new products.

Profitability, cash flow, and the balance sheet

GAAP gross margin rose to 45.5%, while adjusted gross margin improved 65 basis points to 45.6%. The company attributed the adjusted improvement to lower cost of revenue. Total operating expenses increased about 1.9% to $48.4 million, slower than revenue growth, which helped the GAAP operating margin improve to negative 5.4% from negative 6.6%.

Positive adjusted EBITDA does not mean Inogen has reached GAAP profitability. The Q2 reconciliation included $4.7 million of depreciation and amortization, $1.8 million of stock-based compensation, $0.2 million of restructuring charges, and $0.6 million of shareholder engagement and proxy-defense costs.

Inogen ended June with $106.8 million of cash, cash equivalents, marketable securities, and restricted cash, with no outstanding debt. Q2 operating cash flow was positive, but first-half operating cash flow remained negative at $3.7 million, improving from a $12.4 million outflow a year earlier. First-half free cash flow also improved to negative $6.4 million from negative $18.3 million.

The company used $7.5 million to repurchase 1,145,150 shares during the first half. Accounts receivable increased to $46.2 million from $38.9 million at the end of 2025, while inventory rose to $28.6 million from $26.0 million.

Earnings guidance

Inogen raised its full-year adjusted EBITDA outlook and updated its revenue range. For Q3, management expects revenue to be approximately unchanged from the prior-year quarter because of the continuing U.S. channel-mix shift and the timing of purchases by certain international distributors.

The adjusted EBITDA outlook is a non-GAAP measure. Inogen did not provide a reconciliation to the most comparable forward-looking GAAP measure because some adjustments could not be reasonably predicted.

A stronger second half is needed to reach the EBITDA target

The quarter showed improved momentum, but first-half adjusted EBITDA was $1.0 million, down from $2.1 million in the first half of 2025. Based on the approximately $4.0 million full-year target, Inogen would need to generate about $3.0 million of adjusted EBITDA in the second half.

That requirement is notable because Q3 revenue is expected to remain approximately flat year over year. Reaching the full-year target therefore places additional weight on continued gross-margin improvement, expense discipline, and operating leverage rather than rapid near-term revenue growth alone.

Management perspective

CEO Kevin Smith linked the quarter’s performance to continued product demand, new launches, progress in key markets, and better operating leverage. Management is prioritizing investments across growth, profitability, and product development rather than focusing exclusively on top-line expansion.

During the quarter, Inogen launched the Rove 6 portable oxygen concentrator in Canada and completed enrollment and the last patient visit for its Simeox H study in China. Statistical analysis from that study is expected in the second half of 2026, although no financial contribution from these initiatives was quantified.

Recent insider transactions

The supplied six-month insider summary classifies 427,566 shares across 18 transactions as purchases and 21,708 shares across two transactions as sales, producing a net increase of 405,858 shares. However, the latest individual records are dominated by stock awards rather than open-market purchases, so the categories should not be treated as direct evidence of insiders’ outlook.

The supplied transaction data did not disclose share counts for the individual stock awards. A zero reported grant value does not represent an open-market purchase.

Risks investors should monitor

• Continued U.S. weakness: U.S. sales declined 2.3%, rental revenue fell 11.8%, and the rental patient count decreased about 9.7%. Further declines could offset international growth and limit operating leverage.
• Dependence on currency support: Total reported revenue rose 3.0%, but constant-currency growth was only 0.6%. Less favorable exchange rates could reduce reported growth.
• Distributor order timing: Management expects the timing of selected international distributor purchases to affect Q3 revenue, creating potential quarter-to-quarter volatility.
• Profit and cash-flow execution: Inogen remained unprofitable under GAAP, and first-half operating and free cash flow were negative. Achieving the raised EBITDA outlook requires a substantially stronger second-half contribution.

Summary

Inogen’s Q2 2026 results showed modest revenue growth supported by international portable oxygen concentrator demand and favorable currency effects. Gross margin, operating loss, and adjusted EBITDA improved, but U.S. sales and rentals remained under pressure, and first-half cash flow was still negative. The main issues to watch are execution against the higher second-half EBITDA requirement, stabilization of the U.S. business, international distributor ordering patterns, and whether margin gains remain durable.